AZNAstraZenecaRunning, no new patients
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Breast Neoplasms · Breast Cancer · HER2-positive Early Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 927 (final count)
- Started
- Oct 25, 2021
- Main results expected
- Mar 12, 2025
- Fully finished
- Apr 30, 2027
- Results posted
- Jun 9, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Rate of Pathologic Complete Response (pCR).
Measured over: Through to definitive surgery or discontinuation/withdrawal from study, up to a maximum of approximately 40 months from randomization to primary pCR DCO (12MAR2025)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05113251 · record last updated 2026-08-11 · checked 2026-11-09 15:47 UTC